Genzyme, Isis solidify collaboration agreement

Genzyme and Isis Pharmaceuticals completed their agreement for the cholesterol drug candidate, mipomersen. The two companies have been developing an agreement to work together and announced earlier this year that the collaboration will grant Genzyme exclusive rights to the lipid-lowering drug that Isis has in development. 

For the honor, Genzyme will pay Isis $175 million in licensing fees.  Genzyme earlier paid $150 million for 5 million shares of the company's common stock. Isis will continue to contribute funding for the drug's development.

- see the release
- get the full story at the Boston Globe
- read about the deal at RTT News

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.